Cargando…

Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients

BACKGROUND: The current tumor-node-metastasis (TNM) staging system is insufficient to predict outcome of patients with operable Non-Small Cell Lung Cancer (NSCLC) owing to its phenotypic and genomic heterogeneity. Integrating genomic signatures with clinicopathological factors may provide more detai...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jian, Zhou, Lizhi, Huang, Lixia, Gu, Jincui, Li, Shaoli, Liu, Baomo, Feng, Jinlun, Zhou, Yanbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216590/
https://www.ncbi.nlm.nih.gov/pubmed/28057025
http://dx.doi.org/10.1186/s13046-016-0477-x
_version_ 1782491942793248768
author Wu, Jian
Zhou, Lizhi
Huang, Lixia
Gu, Jincui
Li, Shaoli
Liu, Baomo
Feng, Jinlun
Zhou, Yanbin
author_facet Wu, Jian
Zhou, Lizhi
Huang, Lixia
Gu, Jincui
Li, Shaoli
Liu, Baomo
Feng, Jinlun
Zhou, Yanbin
author_sort Wu, Jian
collection PubMed
description BACKGROUND: The current tumor-node-metastasis (TNM) staging system is insufficient to predict outcome of patients with operable Non-Small Cell Lung Cancer (NSCLC) owing to its phenotypic and genomic heterogeneity. Integrating genomic signatures with clinicopathological factors may provide more detailed evaluation of prognosis. METHODS: All 2164 clinically annotated NSCLC samples (1326 in the training set and 838 in the validation set) with corresponding microarray data from 17 cohorts were pooled to develop and validate a clinicopathologic-genomic nomogram based on Cox regression model. Two computational methods were applied to these samples to capture expression pattern of genomic signatures representing biological statuses. Model performance was measured by the concordance index (C-index) and calibration plot. Risk group stratification was proposed for the nomogram. RESULTS: Multivariable analysis of the training set identified independent factors including age, TNM stage, combined prognostic classifier, non-overlapping signature, and the ratio of neutrophil to plasma cells. The C-index of the nomogram for predicting survival was statistically superior to that of the TNM stage (training set, 0.686 vs 0.627, respectively; P < .001; validation set, 0.689 vs 0.638, respectively; P < .001). The calibration plots showed that the predicted 1-, 3- and 5-year survival probabilities agreed well with the actual observations. Stratifying patients into three risk groups detected significant differences among survival curves. CONCLUSIONS: These findings offer preliminary evidence that genomic data provide independent and complementary prognostic information and incorporation of this information can refine prognosis in NSCLC. Prospective studies are required to further explore the value of this composite model for prognostic stratification and tailored therapeutic strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-016-0477-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5216590
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52165902017-01-09 Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients Wu, Jian Zhou, Lizhi Huang, Lixia Gu, Jincui Li, Shaoli Liu, Baomo Feng, Jinlun Zhou, Yanbin J Exp Clin Cancer Res Research BACKGROUND: The current tumor-node-metastasis (TNM) staging system is insufficient to predict outcome of patients with operable Non-Small Cell Lung Cancer (NSCLC) owing to its phenotypic and genomic heterogeneity. Integrating genomic signatures with clinicopathological factors may provide more detailed evaluation of prognosis. METHODS: All 2164 clinically annotated NSCLC samples (1326 in the training set and 838 in the validation set) with corresponding microarray data from 17 cohorts were pooled to develop and validate a clinicopathologic-genomic nomogram based on Cox regression model. Two computational methods were applied to these samples to capture expression pattern of genomic signatures representing biological statuses. Model performance was measured by the concordance index (C-index) and calibration plot. Risk group stratification was proposed for the nomogram. RESULTS: Multivariable analysis of the training set identified independent factors including age, TNM stage, combined prognostic classifier, non-overlapping signature, and the ratio of neutrophil to plasma cells. The C-index of the nomogram for predicting survival was statistically superior to that of the TNM stage (training set, 0.686 vs 0.627, respectively; P < .001; validation set, 0.689 vs 0.638, respectively; P < .001). The calibration plots showed that the predicted 1-, 3- and 5-year survival probabilities agreed well with the actual observations. Stratifying patients into three risk groups detected significant differences among survival curves. CONCLUSIONS: These findings offer preliminary evidence that genomic data provide independent and complementary prognostic information and incorporation of this information can refine prognosis in NSCLC. Prospective studies are required to further explore the value of this composite model for prognostic stratification and tailored therapeutic strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-016-0477-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-05 /pmc/articles/PMC5216590/ /pubmed/28057025 http://dx.doi.org/10.1186/s13046-016-0477-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wu, Jian
Zhou, Lizhi
Huang, Lixia
Gu, Jincui
Li, Shaoli
Liu, Baomo
Feng, Jinlun
Zhou, Yanbin
Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients
title Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients
title_full Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients
title_fullStr Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients
title_full_unstemmed Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients
title_short Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients
title_sort nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable nsclc: a pooled analysis of 2164 patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216590/
https://www.ncbi.nlm.nih.gov/pubmed/28057025
http://dx.doi.org/10.1186/s13046-016-0477-x
work_keys_str_mv AT wujian nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients
AT zhoulizhi nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients
AT huanglixia nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients
AT gujincui nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients
AT lishaoli nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients
AT liubaomo nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients
AT fengjinlun nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients
AT zhouyanbin nomogramintegratinggeneexpressionsignatureswithclinicopathologicalfeaturestopredictsurvivalinoperablensclcapooledanalysisof2164patients